<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006626</url>
  </required_header>
  <id_info>
    <org_study_id>YOUNGBC-7</org_study_id>
    <nct_id>NCT04006626</nct_id>
  </id_info>
  <brief_title>18F-FES PET/CT's Additional Clinical Value in ER+ BC</brief_title>
  <official_title>18F-FES PET/CT Influences the Staging and Management of Newly Diagnosed Oestrogen Receptor‑Positive Breast Cancer Patients: A Retrospective Comparative Study With 18F-FDG PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To figure out whethetr 18F-FES PET/CT could influence the staging and management of newly
      diagnosed Oestrogen Receptor‑positive Breast Cancer Patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Staging of breast cancer</measure>
    <time_frame>6 weeks</time_frame>
    <description>Deliver questionnaire to phycians to investigate the staging of BC according to AJCC 8 (TNM staging).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PET group</arm_group_label>
    <description>the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FES group</arm_group_label>
    <description>the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with breast cancer (according to ICD-10) with confirmed metastasis,
        regardless of being de novo diagnosed or progressed from a non-metastatic stage
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed immunohistochemical confirmed oestrogen receptor
             (ER)-positive breast cancer

          -  Patients underwent both 18F-FES PET/CT and 18F-FDG PET/CT in Fudan University Shanghai
             Cancer Center within 1 week after diagnosis

          -  Patients with available medical history

        Exclusion Criteria:

          -  Patients with incomplete medical history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biyun Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biyun Wang, MD</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Biyun Wang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

